Targeting menin for precision therapy in high-risk acute myeloid leukemia
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinica...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000852 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688047728197632 |
|---|---|
| author | Abdur Jamil Zaheer Qureshi Zain Mary El-amir Gillian Kupakuwana-Suk Hamzah Akram Mohsin Ahmad Eric Huselton |
| author_facet | Abdur Jamil Zaheer Qureshi Zain Mary El-amir Gillian Kupakuwana-Suk Hamzah Akram Mohsin Ahmad Eric Huselton |
| author_sort | Abdur Jamil |
| collection | DOAJ |
| description | Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets. |
| format | Article |
| id | doaj-art-e0bdf04d5b7a48fa972467a665841842 |
| institution | DOAJ |
| issn | 2213-0489 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-e0bdf04d5b7a48fa972467a6658418422025-08-20T03:22:08ZengElsevierLeukemia Research Reports2213-04892025-01-012310049510.1016/j.lrr.2024.100495Targeting menin for precision therapy in high-risk acute myeloid leukemiaAbdur Jamil0Zaheer Qureshi1Zain Mary El-amir2Gillian Kupakuwana-Suk3Hamzah Akram4Mohsin Ahmad5Eric Huselton6Department of Medicine, Samaritan Medical Centre Watertown, NY, USA; Corresponding author at: Department of Medicine, Samaritan Medical Centre Watertown, NY, USA.The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, Connecticut, USAUniversity of Michigan, Ann Arbor, MI, USALeukemia Fellowship Program at The Ottawa Hospital Division of Hematology Department of Medicine University of Ottawa, Ottawa, CanadaHamilton Health Sciences, Hamilton, Ontario, CanadaCHRISTUS Southeast Texas - St. Elizabeth Hospital, Beaumont, Texas, USAUniversity of Rochester, Department of Hematology/Oncology, Rochester, NY, USAObjective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.http://www.sciencedirect.com/science/article/pii/S2213048924000852Acute myeloid leukemiaRevumenibKMT2AMenin inhibition therapy |
| spellingShingle | Abdur Jamil Zaheer Qureshi Zain Mary El-amir Gillian Kupakuwana-Suk Hamzah Akram Mohsin Ahmad Eric Huselton Targeting menin for precision therapy in high-risk acute myeloid leukemia Leukemia Research Reports Acute myeloid leukemia Revumenib KMT2A Menin inhibition therapy |
| title | Targeting menin for precision therapy in high-risk acute myeloid leukemia |
| title_full | Targeting menin for precision therapy in high-risk acute myeloid leukemia |
| title_fullStr | Targeting menin for precision therapy in high-risk acute myeloid leukemia |
| title_full_unstemmed | Targeting menin for precision therapy in high-risk acute myeloid leukemia |
| title_short | Targeting menin for precision therapy in high-risk acute myeloid leukemia |
| title_sort | targeting menin for precision therapy in high risk acute myeloid leukemia |
| topic | Acute myeloid leukemia Revumenib KMT2A Menin inhibition therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2213048924000852 |
| work_keys_str_mv | AT abdurjamil targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT zaheerqureshi targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT zainmaryelamir targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT gilliankupakuwanasuk targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT hamzahakram targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT mohsinahmad targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia AT erichuselton targetingmeninforprecisiontherapyinhighriskacutemyeloidleukemia |